{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "regularMarketChangePercent": -0.3688531, "regularMarketPrice": 12.155, "exchange": "FRA", "shortName": "IMMUNOGEN INC.  DL-,01", "longName": "ImmunoGen, Inc.", "messageBoardId": "finmb_29794", "exchangeTimezoneName": "Europe/Berlin", "market": "dr_market", "regularMarketTime": 1683871252, "regularMarketDayHigh": 12.155, "regularMarketDayRange": "12.155 - 12.155", "regularMarketDayLow": 12.155, "regularMarketVolume": 280, "regularMarketPreviousClose": 12.2, "bid": 12.345, "ask": 12.42, "bidSize": 1000, "askSize": 1000, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 12.155, "averageDailyVolume3Month": 217, "averageDailyVolume10Day": 1277, "fiftyTwoWeekLowChange": 9.132, "fiftyTwoWeekLowChangePercent": 3.0208402, "fiftyTwoWeekRange": "3.023 - 12.755", "fiftyTwoWeekHighChange": -0.6000004, "fiftyTwoWeekHighChangePercent": -0.047040407, "fiftyTwoWeekLow": 3.023, "fiftyTwoWeekHigh": 12.755, "earningsTimestamp": 1682683200, "earningsTimestampStart": 1690461000, "earningsTimestampEnd": 1690806600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.87, "epsForward": -0.8, "epsCurrentYear": -0.72, "priceEpsCurrentYear": -16.881943, "sharesOutstanding": 226070000, "bookValue": 0.539, "fiftyDayAverage": 4.71369, "fiftyDayAverageChange": 7.44131, "fiftyDayAverageChangePercent": 1.5786592, "twoHundredDayAverage": 4.9107723, "twoHundredDayAverageChange": 7.2442274, "twoHundredDayAverageChangePercent": 1.4751707, "marketCap": 2747880704, "forwardPE": -15.193749, "priceToBook": 22.551022, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.1 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 951289200000, "priceHint": 2, "regularMarketChange": -0.045000076, "symbol": "IMU.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451-1477", "country": "United States", "phone": "781 895 0600", "website": "https://www.immunogen.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 277, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Joseph Enyedy", "age": 58, "title": "Pres, CEO & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 1284825, "fmt": "1.28M", "longFmt": "1,284,825"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 780281, "fmt": "780.28k", "longFmt": "780,281"}}, {"maxAge": 1, "name": "Ms. Renee  Lentini", "age": 44, "title": "Interim CFO, VP of Fin. & Chief Accounting Officer", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 430518, "fmt": "430.52k", "longFmt": "430,518"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 243574, "fmt": "243.57k", "longFmt": "243,574"}}, {"maxAge": 1, "name": "Dr. Anna  Berkenblit M.D., MM.Sc", "age": 52, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 717040, "fmt": "717.04k", "longFmt": "717,040"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 429762, "fmt": "429.76k", "longFmt": "429,762"}}, {"maxAge": 1, "name": "Ms. Stacy A. Coen", "age": 51, "title": "Sr. VP & Chief Bus. Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 584042, "fmt": "584.04k", "longFmt": "584,042"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 10100, "fmt": "10.1k", "longFmt": "10,100"}}, {"maxAge": 1, "name": "Dr. Michael J. Vasconcelles M.D., Ph.D.", "age": 59, "title": "Exec. VP of Research, Devel. & Medical Affairs", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 304620, "fmt": "304.62k", "longFmt": "304,620"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Anabel  Chan", "title": "Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Daniel S. Char J.D.", "age": 61, "title": "Sr. VP, Chief Legal Officer & Sec.", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Courtney  O'Konek", "title": "Sr. Director of Corp. Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Audrey  Bergan", "title": "Sr. VP & Chief HR Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Theresa G. Wingrove", "age": 64, "title": "Sr. VP of Regulatory Affairs & Quality", "yearBorn": 1958, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 3, "compensationRisk": 7, "shareHolderRightsRisk": 5, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}